Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study aims to compare the response of triple-negative breast cancer with deficient
homologous recombination to intensified alkylating chemotherapy versus standard chemotherapy
with dose dense AC and/or Docetaxel-Capecitabine.